Roberto Ferrara

List of Publications by Citations

63 papers	2,922 citations	22 h-index	54 g-index
67 ext. papers	3,880 ext. citations	5.3 avg, IF	5.25 L-index

#	Paper	IF	Citations
63	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2018**, 36, 2872-2878	2.2	477
62	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. *JAMA Oncology*, **2018**, 4, 1543-1552	13.4	380
61	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA Oncology*, **2018**, 4, 351-357	13.4	357
60	Hyperprogressive disease: recognizing a novel pattern to improve patient management. *Nature Reviews Clinical Oncology*, **2018**, 15, 748-762	19.4	206
59	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. *European Journal of Cancer*, **2018**, 88, 38-47	7.5	178
58	Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D. *Journal of Pathology*, **2017**, 241, 488-500	9.4	122
57	Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. *European Journal of Cancer*, **2019**, 106, 144-159	7.5	108
56	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. *Journal of Thoracic Oncology*, **2019**, 14, 1244-1254	8.9	106
55	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. *ESMO Open*, **2019**, 4, e000457	6	93
54	Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 27-45	8.9	90
53	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. *Cancer Treatment Reviews*, **2019**, 75, 39-51	14.4	85
52	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. *Cancer Treatment Reviews*, **2017**, 60, 60-68	14.4	83
51	Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study. *European Journal of Cancer*, **2019**, 109, 28-35	7.5	50
50	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. *Cancers*, **2019**, 11,	6.6	39
49	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer. *JAMA Oncology*, **2020**, 6, 1039-1046	13.4	36
48	Do immune checkpoint inhibitors need new studies methodology?. *Journal of Thoracic Disease*, **2018**, 10, S1564-S1580	2.6	35
47	Progress in the Management of Advanced Thoracic Malignancies in 2017. *Journal of Thoracic Oncology*, **2018**, 13, 301-322	8.9	34

46	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. *Clinical Cancer Research*, **2021**, 27, 492-503	12.9	31
45	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. *Lung Cancer*, **2019**, 137, 38-42	5.9	29
44	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. *Oncologist*, **2020**, 25, 94-98	5.7	26
43	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. *European Journal of Cancer*, **2019**, 116, 182-189	7.5	23
42	Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2253-2266	4	22
41	Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients. *European Journal of Cancer*, **2019**, 108, 88-96	7.5	22
40	Tubulin inhibitors in non-small cell lung cancer: looking back and forward. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 1113-29	4	18
39	Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis. *Immunotherapy*, **2021**, 13, 621-631	3.8	16
38	Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. *British Journal of Cancer*, **2020**, 122, 340-347	8.7	15
37	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). *Cancers*, **2020**, 12,	6.6	14
36	Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer. *Cancers*, **2020**, 12,	6.6	14
35	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers-Letter. *Clinical Cancer Research*, **2019**, 25, 3468	12.9	13
34	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. *The Cochrane Library*, **2020**, 12, CD013257	5.2	12
33	The development of PARP as a successful target for cancer therapy. *Expert Review of Anticancer Therapy*, **2018**, 18, 161-175	3.5	12
32	Afatinib in patients with metastatic HER2-mutant lung cancers: An international multicenter study.. *Journal of Clinical Oncology*, **2017**, 35, 9071-9071	2.2	12
31	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. *Journal of Clinical Oncology*, **2018**, 36, 9003-9003	2.2	12
30	The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives. *Expert Opinion on Biological Therapy*, **2015**, 15, 1359-70	5.4	11
29	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. *Lung Cancer*, **2021**, 152, 165-173	5.9	11

28	Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a new frontier?. *Anti-Cancer Agents in Medicinal Chemistry*, **2015**, 15, 307-13	2.2	10
27	Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer. *Current Oncology Reports*, **2020**, 22, 41	6.3	10
26	Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study. *Oncotarget*, **2018**, 9, 1906-1914	3.3	10
25	ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. *Respiratory Research*, **2016**, 17, 105	7.3	9
24	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. *The Cochrane Library*, **2021**, 4, CD013257	5.2	8
23	Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).. *Journal of Clinical Oncology*, **2019**, 37, 9107-9107	2.2	7
22	Atypical patterns of response and progression in the era of immunotherapy combinations. *Future Oncology*, **2020**, 16, 1707-1713	3.6	7
21	An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. *Expert Opinion on Investigational Drugs*, **2015**, 24, 1143-61	5.9	5
20	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. *Future Oncology*, **2019**, 15, 2743-2757	3.6	5
19	Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy.. *JCO Precision Oncology*, **2020**, 4, 829-840	3.6	5
18	Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer-In Reply. *JAMA Oncology*, **2019**, 5, 744	13.4	4
17	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. *Clinical Lung Cancer*, **2020**, 21, e337-e348	4.9	4
16	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.. *Cancers*, **2022**, 14,	6.6	4
15	Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. *Translational Lung Cancer Research*, **2020**, 9, 617-628	4.4	3
14	Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. *Critical Reviews in Oncology/Hematology*, **2021**, 160, 103299	7	3
13	Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2429-2438	7.4	3
12	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. *Clinical Lung Cancer*, **2019**, 20, e652-e660	4.9	2
11	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. *The Cochrane Library*, **2019**,	5.2	2

List of Publications

10	Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report. *Future Science OA*, **2015**, 1, FSO29	2.7	2
9	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. *Cancers*, **2021**, 13,	6.6	2
8	Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.. *Journal of Clinical Oncology*, **2017**, 35, 9089-9089	2.2	1
7	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. *Precision Cancer Medicine*, **2019**, 2, 35-35	1	1
6	Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments. *Cellular Immunology*, **2021**, 362, 104301	4.4	0
5	Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations. *Translational Lung Cancer Research*, **2021**, 10, 2955-2969	4.4	0
4	Genomics and Immunomics in the Treatment of Urothelial Carcinoma. *Current Oncology*, **2022**, 29, 3499-3518	2.5	0
3	Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).. *Journal of Clinical Oncology*, **2018**, 36, 9066-9066	2.2	
2	Facing the First-line in Metastatic Non-small-cell Lung Cancer Immunotherapy and Chemotherapy. *European Oncology and Haematology*, **2020**, 16, 39	0.1	
1	Prognostic value of ALK gene copy number (GCN) status for resected and metastatic non-small-cell lung cancer (NSCLC): A retrospective analysis of 205 patients (pts).. *Journal of Clinical Oncology*, **2014**, 32, e19059-e19059	2.2	